These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 15939202)

  • 41. Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop.
    Buckley LA; Benson K; Davis-Bruno K; Dempster M; Finch GL; Harlow P; Haggerty HG; Hart T; Kinter L; Leighton JK; McNulty J; Roskos L; Saber H; Stauber A; Tabrizi M
    Int J Toxicol; 2008; 27(4):303-12. PubMed ID: 18821393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The other side of clinical trial monitoring; assuring data quality and procedural adherence.
    Williams GW
    Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct.
    Hondeghem LM
    Eur J Pharmacol; 2008 Apr; 584(1):1-9. PubMed ID: 18304526
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Statistical issues and techniques appropriate for developmental neurotoxicity testing: a report from the ILSI Research Foundation/Risk Science Institute expert working group on neurodevelopmental endpoints.
    Holson RR; Freshwater L; Maurissen JP; Moser VC; Phang W
    Neurotoxicol Teratol; 2008; 30(4):326-48. PubMed ID: 17681748
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Direct dosing of preweaning rodents in toxicity testing and research: deliberations of an ILSI RSI Expert Working Group.
    Moser VC; Walls I; Zoetis T
    Int J Toxicol; 2005; 24(2):87-94. PubMed ID: 16036767
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interpreting epidemiologic studies of developmental neurotoxicity: conceptual and analytic issues.
    Bellinger DC
    Neurotoxicol Teratol; 2009; 31(5):267-74. PubMed ID: 19595760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design of the Behavior Enhances Drug Reduction of Incontinence (BE-DRI) study.
    Urinary Incontinence Treatment Network (UITN)
    Contemp Clin Trials; 2007 Jan; 28(1):48-58. PubMed ID: 16919506
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Methodological issues in research on developmental exposure to neurotoxic agents.
    Jacobson JL; Jacobson SW
    Neurotoxicol Teratol; 2005; 27(3):395-406. PubMed ID: 15939200
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop.
    Klein HG; Glynn SA; Ness PM; Blajchman MA;
    Transfusion; 2009 Jun; 49(6):1262-8. PubMed ID: 19392769
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Considerations in chronic toxicity testing: the chemical, the dose, the design.
    Munro IC
    J Environ Pathol Toxicol; 1977; 1(2):183-97. PubMed ID: 553130
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A 'best practices' approach to neuropathologic assessment in developmental neurotoxicity testing--for today.
    Bolon B; Garman R; Jensen K; Krinke G; Stuart B;
    Toxicol Pathol; 2006; 34(3):296-313. PubMed ID: 16698729
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
    Zhu Y; Wang T; Jelsovsky JZ
    Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Building a scientific framework for studying hormonal effects on behavior and on the development of the sexually dimorphic nervous system.
    Li AA; Baum MJ; McIntosh LJ; Day M; Liu F; Gray LE
    Neurotoxicology; 2008 May; 29(3):504-19. PubMed ID: 18502513
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional assays for neurotoxicity testing.
    Moser VC
    Toxicol Pathol; 2011 Jan; 39(1):36-45. PubMed ID: 21075917
    [TBL] [Abstract][Full Text] [Related]  

  • 55. AGAATI/ECVAM Workshop on the Validation of Alternative Methods for the Potency Testing of Vaccines.
    Halder M; Hendriksen CF; Spieser JM
    ALTEX; 1998; 15(5):5. PubMed ID: 11178524
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Integration of epidemiology and animal neurotoxicity data for risk assessment.
    Li AA; Levine TE; Burns CJ; Anger WK
    Neurotoxicology; 2012 Aug; 33(4):823-32. PubMed ID: 22327016
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of toxicokinetics to support chemical evaluation: Informing high dose selection and study interpretation.
    Creton S; Saghir SA; Bartels MJ; Billington R; Bus JS; Davies W; Dent MP; Hawksworth GM; Parry S; Travis KZ
    Regul Toxicol Pharmacol; 2012 Mar; 62(2):241-7. PubMed ID: 22198561
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Breakout session summary from AAPS/CRS joint workshop on critical variables in the in vitro and in vivo performance of parenteral sustained release products.
    Martinez MN; Rathbone MJ; Burgess D; Huynh M
    J Control Release; 2010 Feb; 142(1):2-7. PubMed ID: 19808069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The IPCS Collaborative Study on Neurobehavioral Screening Methods: II. Protocol design and testing procedures.
    Moser VC; Tilson HA; MacPhail RC; Becking GC; Cuomo V; Frantík E; Kulig BM; Winneke G
    Neurotoxicology; 1997; 18(4):929-38. PubMed ID: 9457730
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Testing programs for behavioral toxicity: test guidelines, methodologies and interpretation of data. Boston, November 4-5, 1987. Proceedings.
    Toxicol Ind Health; 1989 Mar; 5(2):157-260. PubMed ID: 2728011
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.